• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nanoform Finland

0.86 EUR

-3.16 %

3,763 following

NANOFH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-3.16 %
-6.43 %
+40.82 %
-26.71 %
-19.27 %
-15.78 %
-63.29 %
-87.40 %
-82.99 %

Nanoform Finland operates in the medical technology sector. The company specializes in research and development of nanoparticle technology used to create nanoparticles in pharmaceuticals. The technology is used as a complement in the production process and is used for the treatment of diseases such as ALS and Alzheimer's. Customers consist of players in the global pharmaceutical industry, with the largest operations in the Nordic market. Nanoform Finland is headquartered in Helsinki.

Read more
Market cap
73.66M EUR
Turnover
62.98K EUR
Revenue
3.55M
EBIT %
-520.56 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
The company has certainly landed in quite a sweet spot. Partners see the value add of Nanoform’s technology as so significant that they are willing to cover the trial, development, and production costs on Nanoform’s behalf, yet Nanoform’s margins remain absolutely outrageous. Granted...
5/19/2026, 10:41 AM
20
I just listened to the Q1 webcast, and here are a few points regarding the nanoformulation of biological compounds that caught my attention in the management’s comments. The production capacity of the biologics line is already about 10 kg per week. Management commented that one thing...
5/19/2026, 9:21 AM
by jerej
20
Kauppalehti has published another hype interview with the Nanoform brothers; I figured the old patterns would hold true and the share price would jump. As a warning to new faces: so far, I’ve noticed that every time there’s a similar story in Kauppalehti or elsewhere, or a target...
6/1/2026, 9:06 AM
by JusaVaan
11
Nordic Listed Leaders Meet Finland's Future Leaders 2026 — Nordic Listed Leaders Nordic Listed Leaders recognised six of Finland's most promising young listed-company leaders in Helsinki today; a spotlight on the next generation of leadership inside listed companies, which Finnish...
6/5/2026, 6:07 PM
by Latupuikko
10
I found this to be an encouraging report. It was good to hear that the partners are footing the bill for the additional work and modifications on nanoenzalutamide. A 94% gross margin is pretty outrageous if this operation actually scales commercially .
5/19/2026, 5:59 AM
10
Q1 report is out. Regarding the nanoenzalutamide project, it says: ” On the small molecules side, our nanoenzalutamide program reached an important inflection point during the quarter. Feedback from a European scientific advice meeting confirmed the strong scientific rationale for...
5/19/2026, 5:47 AM
by JusaVaan
9
Halozyme recently acquired two companies producing these other hyper-concentrated biological compounds, Elektrofi for $900M and Surf Bio for $400M. Both of those are admittedly a bit further along in biological drug substances than Nanoform and are starting Phase 1 trials in the ...
5/12/2026, 1:37 PM
by jerej
8
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20.8
2026

Interim report Q2'26

11.11
2026

Interim report Q3'26

25.2
2027

Annual report '26

Regulatory press release6/10/2026, 10:30 AM

Nanoform Finland Plc – Manager’s Transactions – Jeanne Thoma

Nanoform Finland
Regulatory press release6/10/2026, 10:30 AM

Nanoform Finland Plc – Manager’s Transactions – Miguel Calado

Nanoform Finland
Regulatory press release6/10/2026, 5:30 AM

Share subscriptions based on the resolution by Nanoform Finland Plc’s Annual General Meeting 2026 on remuneration of the Board of Directors

Nanoform Finland

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/29/2026, 4:10 PM

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key individuals

Nanoform Finland
Regulatory press release5/19/2026, 5:10 AM

Nanoform Q1 2026 report - Record first quarter revenue, income and gross margin, first exclusivity deal signed around our Biologics technology

Nanoform Finland
Regulatory press release5/12/2026, 5:00 AM

Inside information: Nanoform Signs First Exclusivity Agreement for Ultra-High Concentration Subcutaneous Delivery

Nanoform Finland
Press release5/5/2026, 8:00 AM

Invitation to Nanoform’s Q1 2026 Report Presentation

Nanoform Finland
Regulatory press release4/21/2026, 9:20 AM

Resolutions of Nanoform Finland Plc's Annual General Meeting on April 21, 2026

Nanoform Finland
Regulatory press release4/21/2026, 9:20 AM

Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc

Nanoform Finland
Regulatory press release4/2/2026, 6:30 AM

Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen

Nanoform Finland
Regulatory press release4/2/2026, 6:30 AM

Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström

Nanoform Finland
Regulatory press release3/30/2026, 6:10 PM

Inside information: Feedback from European Scientific Advice Meeting with Reference Member State Will Delay Submission of European Marketing Authorization Application Planned Initially for May 2026

Nanoform Finland
Regulatory press release3/19/2026, 6:00 PM

Notice to the Annual General Meeting of NANOFORM FINLAND Plc

Nanoform Finland
Regulatory press release3/2/2026, 2:00 PM

Nanoform Finland Plc – Manager’s Transactions – David Rowe

Nanoform Finland
Regulatory press release3/2/2026, 2:00 PM

Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen

Nanoform Finland
Regulatory press release3/2/2026, 2:00 PM

Nanoform Finland Plc – Manager’s Transactions – Christian Jones

Nanoform Finland
Regulatory press release3/2/2026, 2:00 PM

Nanoform Finland Plc – Manager’s Transactions – Edward Hæggström

Nanoform Finland
Regulatory press release3/2/2026, 2:00 PM

Nanoform Finland Plc – Manager’s Transactions – Antonio Da Silva

Nanoform Finland
Regulatory press release3/2/2026, 2:00 PM

Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström

Nanoform Finland
Regulatory press release3/2/2026, 6:10 AM

The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees

Nanoform Finland